ACRV Acrivon Therapeutics, Inc. Common Stock
USHealthcareAs of 2026-07-10 16:00
Why ACRV matters now
Acrivon Therapeutics, Inc. Common Stock (ACRV) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.96 with -4.39% on the session and $61.9M in market capitalization; recent performance reads 1-month -1.88% and YTD -34.85%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-19.0M, and EPS of $-0.49. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -133.8%.
The latest indexable market news headline is "Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes Blume-Jensen Peter filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.64
P/S
0.00
EV/EBITDA
-0.22
DCF Value
$0.95
FCF Yield
-133.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-64.4%
ROA
-71.7%
ROIC
-84.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-19.0M | $-0.49 |
| Q4 2025 | $0.00 | $-19.0M | $-0.49 |
| FY 2025 | $0.00 | $-77.9M | $-2.02 |
| Q3 2025 | $0.00 | $-18.2M | $-0.47 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$21.83
Target (Median)
$20.00
Target Range
$17.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.91
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.